133 patents currently held
55 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next US patent term in the Henry Company LLC portfolio ends in Feb 2027, and more of its terms end in 2036 (18) than in any other year. from the record
Of the 55 now held by other companies, 20 name Kyocera Corporation as their current owner, and 35 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Feb 2027
Next term end
100
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2029 · High confidence
Also notable
Ends Apr 2029 · High confidence
Also notable
Ends Sep 2036 · High confidence
Also notable
Ends Apr 2029 · High confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends Aug 2032 · High confidence
Also notable
Ends Jan 2030 · High confidence
Also notable
Ends Nov 2034 · High confidence
Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US 9,206,481
The most cited patent in this portfolio, cited by 120 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2029.
Apparatus and Method for Controlled Depth of Injection into Myocardial Tissue
US 8,801,665
Cited by 47 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Low-Dust Products Using a Wax Emulsion
US 10,801,217
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Electrospun Dextran Fibers and Devices Formed Therefrom
US 9,399,082
Cited by 60 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Vaccine Compositions of Herpesvirus Envelope Protein Combinations to Induce Immune Response
US 11,572,389
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038.
Isolation and Detection of Cancer Cells
US 9,335,327
Cited by 28 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Methods and Compositions Based on Shiga Toxin Type 2 Protein
US 8,969,529
Cited by 24 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Water-Resistant Products Using a Wax Emulsion
US 9,828,504
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 20 to 25, 2026 · next Dec 20
- 4 fees due Jan 7 to 30, 2027 · next Jan 7
- 2 fees due Feb 6 to 20, 2027 · next Feb 6
- 2 fees due Mar 5 to 17, 2027 · next Mar 5
- 3 fees due Apr 8 to 24, 2027 · next Apr 8
- 1 fee due May 17, 2027The maintenance fee for Compositions Containing Nucleosides and Manganese and Their Uses (US 9,186,406) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 3 fees due Jun 8 to 24, 2027 · next Jun 8
- 2 fees due Jul 9 to 12, 2027 · next Jul 9
- 2 fees due Aug 23 to 27, 2027 · next Aug 23
- 3 fees due Oct 23 to 30, 2027 · next Oct 23
- 1 fee due Nov 10, 2027The maintenance fee for Isolation and Detection of Cancer Cells (US 9,335,327) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 24, 2026
- 6 terms have ended since Aug 24, 2026
- Oct 9 US 10,093,901 Design and Use of Specific Regulatory T-Cells to Induce Immune Tolerance · lapsed on the fee record
- Oct 4 US 11,458,233 Method for Detecting Intravascular Volume Depletion During a Hemodialysis Session · lapsed on the fee record
- Sep 25 US 10,081,658 Truncated HIV Envelope Proteins (ENV), Methods and Compositions Related Thereto · lapsed on the fee record
- Sep 25 US 10,081,637 Pyrazole Compounds as Modulators of FSHR and Uses Thereof · lapsed on the fee record
- Sep 8 US 9,720,000 Targeted Identification of Immunogenic Peptides · term ended
- Sep 8 US 9,050,322 Targeted Identification of Immunogenic Peptides · term ended
What they patent
The largest of its 100 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,988,971 | Human Monoclonal Antibodies Against Hendra and Nipah Viruses In force · High confidence | In force | High confidence | |
| US 7,893,094 | Amphiphilic Pyridinium Compounds, Method of Making and Use Thereof In force · High confidence | In force | High confidence | |
| US 7,875,017 | Cardiac Repair, Resizing and Reshaping Using the Venous System of the Heart held by Henry Ford Health System In force · High confidence | In force | High confidence | |
| US 8,945,573 | Targeted Identification of Immunogenic Peptides In force · Medium confidence | In force | Medium confidence | |
| US 8,865,171 | Soluble Forms of Hendra and Nipah Virus G Glycoprotein In force · High confidence | In force | High confidence | |
| US 7,880,465 | Method and Apparatus for Contrast Inflow Dynamic MR Angiography In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 8,801,665 | Apparatus and Method for Controlled Depth of Injection into Myocardial Tissue held by Henry Ford Health System In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 9,399,082 | Electrospun Dextran Fibers and Devices Formed Therefrom In force · High confidence | In force | High confidence | |
| US 10,046,081 | Electrospun Dextran Fibers and Devices Formed Therefrom In force · High confidence | In force | High confidence | |
| US 12,171,888 | Electrospun Dextran Fibers and Devices Formed Therefrom In force · High confidence | In force | High confidence |
Also on record, not counted in the 133: 55 patents in force now held by others · 70 patents ended · 74 applications pending · 99 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.